Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2019
June 2019, Vol 10, No 3
June 2019, Vol 10, No 3
Tibsovo Now Indicated for First-Line Treatment of Patients with AML and IDH1 Mutation
FDA Approvals, News & Updates
June 2019, Vol 10, No 3
On May 2, 2019, the FDA approved ivosidenib (Tibsovo; Agios) for patients with newly diagnosed acute myeloid leukemia (AML) and a susceptible
IDH1
mutation, as detected by an FDA-approved test, in patients aged ≥75 years or those who have comorbidities that preclude the use of intensive induction chemotherapy. Ivosidenib was originally approved in 2018 for relapsed or refractory AML with
IDH1
mutation.
Read Article
Keytruda plus Inlyta New First-Line Combination Approved for Advanced Renal-Cell Carcinoma
FDA Approvals, News & Updates
June 2019, Vol 10, No 3
On April 19, 2019, the FDA accelerated the approval of pembrolizumab (Keytruda; Merck) plus axitinib (Inlyta; Pfizer) as first-line treatment of patients with advanced renal-cell carcinoma (RCC). Keytruda was previously approved as a single agent or in combination with other agents for many other indications and types of cancers.
Read Article
Balversa First Targeted Drug FDA Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
FDA Approvals, News & Updates
June 2019, Vol 10, No 3
On April 12, 2019, the FDA accelerated the approval of erdafitinib (Balversa; Janssen), a fibroblast growth factor receptor (FGFR) kinase inhibitor, for the treatment of adults with locally advanced or metastatic urothelial carcinoma and a susceptible
FGFR3
or
FGFR2
genetic alteration, as detected by an FDA-approved test, whose disease progressed after platinum-containing chemotherapy, making it the first targeted drug to receive approval for this patient population.
Read Article
Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation
By
Phoebe Starr
Leukemia
,
Hematologic Malignancies
June 2019, Vol 10, No 3
Atlanta, GA—Treatment with gilteritinib (Xospata) significantly improved overall survival (OS) with less toxicity compared with chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) and
FLT3
mutation, according to the final results of ADMIRAL, a phase 3 clinical trial presented at the 2019 American Association for Cancer Research meeting.
Read Article
Paradigm Shift: Ibrutinib plus Rituximab Front-Line Therapy for Patients Age 70 or Younger with CLL
By
Phoebe Starr
Leukemia
,
Hematologic Malignancies
June 2019, Vol 10, No 3
San Diego, CA—The combination of the targeted therapy ibrutinib (Imbruvica), a protein kinase inhibitor, and the monoclonal antibody rituximab (Rituxan) extends disease-free survival by 65% and overall survival (OS) by 83% compared with standard-of-care chemotherapy with the fludarabine plus cyclophosphamide and rituximab (FCR) regimen as first-line therapy in patients with chronic lymphocytic leukemia (CLL) under age 70, according to results of the phase 3 ECOG-ACRIN 1912 trial presented at a late-breaking abstract session at ASH 2018.
Read Article
CAR T-Cell Therapy Augments Response to Ibrutinib in Chronic Lymphocytic Leukemia
By
Phoebe Starr
Leukemia
,
Hematologic Malignancies
June 2019, Vol 10, No 3
San Diego, CA—Results with chimeric antigen receptor (CAR) T-cell therapy have been less robust in chronic lymphocytic leukemia (CLL) compared with B-cell acute lymphocytic leukemia and diffuse large B-cell lymphoma. Preliminary studies presented at ASH 2018 suggested that a strategy of using CAR T-cell therapy to augment the response to ibrutinib (Imbruvica) holds promise in patients with CLL.
Read Article
Revised Risk Categories in NCCN Guideline for Metastatic Renal-Cell Carcinoma Affects Preferred Front-Line Options
By
Wayne Kuznar
2019 NCCN Conference
June 2019, Vol 10, No 3
Orlando, FL—The updated guideline on the management of metastatic renal-cell carcinoma (RCC) from the National Comprehensive Cancer Network (NCCN), version 3.2019, underwent a major shift in its risk categories to define preferred and alternative first-line treatments.
Read Article
Updated NCCN Guideline Strongly Recommends Germline Testing for All Patients with Pancreatic Cancer
By
Wayne Kuznar
2019 NCCN Conference
,
Pancreatic Cancer
June 2019, Vol 10, No 3
Orlando, FL—Germline testing should now be considered for any patient with pancreatic cancer, and molecular analysis of tumors should be considered in patients with metastatic disease, according to the updated National Comprehensive Cancer Network (NCCN) guideline for pancreatic cancer presented at the 2019 NCCN Conference.
Read Article
New Targeted Therapies for Metastatic Colorectal Cancer Recommended in the Updated NCCN Guideline
By
Wayne Kuznar
2019 NCCN Conference
June 2019, Vol 10, No 3
Orlando, FL—A growing number of targeted therapies and immunotherapies are now recommended in the updated National Comprehensive Cancer Network (NCCN) guideline for metastatic colorectal cancer (CRC). New first-line immunotherapy options for patients with mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) CRC are also listed in the new guideline.
Read Article
Assessment of Opioid Misuse and Abuse Should Be Part of Cancer Pain Management
By
Wayne Kuznar
2019 NCCN Conference
June 2019, Vol 10, No 3
Orlando, FL—Maintaining patient safety and minimizing the risks for opioid misuse and abuse in the management of cancer pain require proper assessment and new strategies for pain management that include integrative interventions, according to Judith A. Paice, PhD, RN, Director, Cancer Pain Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago. She discussed this topic at the 2019 National Comprehensive Cancer Network (NCCN) Conference.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma